medigraphic.com

2022, Number 1

<< Back Next >>

Rev Fac Med UNAM 2022; 65 (1)

Autism Spectrum Disorder (ASD)

Celis AG, Ochoa MMG

Language: Spanish
References: 56
Page: 7-20
PDF size: 350.56 Kb.


Text Extraction

Autism Spectrum Disorder (ASD) is a neurodevelopmental disorder with multidimensional involvement, characterized by decreased social interaction with deficiencies in communication through verbal and nonverbal language and inflexibility in behavior by presenting repetitive behaviors and restricted interests. Its etiopathogenesis and related risk factors are increasingly being better studied. This is a frequent clinical entity. Approximately 1 in 160 children have some degree of autism globally. However, it is rarely diagnosed, being identified until the appearance of its comorbidity with other psychiatric disorders such as anxiety or depression. Currently, there is no specific treatment for the nuclear symptoms of autism, however, there are different therapeutic and pharmacological options that improve the quality of life of its carriers.


REFERENCES

  1. Artigas-Pallares J, Paula I. El autismo 70 años después de Leo Kanner y Hans Asperger. Rev Asoc Esp Neuropsiquiatr. 2012;32(115):567-87.

  2. Moskowitz A, Heim G. Eugen Bleuler’s Dementia praecox or the group of schizophrenias (1911): a centenary appreciation and reconsideration. Schizophr Bull. 2011;37(3):471-9.

  3. Kanner L. The conception of wholes and parts in early infantile autism. Am J Psychiatry. 1951;108(1):23-6.

  4. Wing L. Asperger’s syndrome: a clinical account. Psychol Med. 1981;11(1):115-29.

  5. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders (DSM-II). 2nd ed. Arlington, TX: American Psychiatric Association Publishing; 1968.

  6. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders (DSM-III®). 3rd ed. Arlington, TX: American Psychiatric Association Publishing; 1987.

  7. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders (DSM-IV®). 4th ed. Arlington, TX: American Psychiatric Association Publishing; 2000.

  8. Wing L, Gould J. Severe impairments of social interaction and associated abnormalities in children: epidemiology and classification. J Autism Dev Disord. 1979;9(1):11-29.

  9. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders (DSM-5®). 5th ed. Arlington, TX: American Psychiatric Association Publishing; 2013.

  10. DSM-5 [Internet]. Dsm5.org. [Citado: 2015 de octubre de 2020]. Disponible en: http://www.dsm5.org Autism Spectrum Disorder Fact Sheet.

  11. Lundström S, Reichenberg A, Anckarsäter H, Lichtenstein P, Gillberg C. Autism phenotype versus registered diagnosis in Swedish children: prevalence trends over 10 years in general population samples. BMJ. 2015;350(apr28 2):h1961.

  12. Lyall K, Baker A, Hertz-Picciotto I, Walker CK. Infertility, and its treatments in association with autism spectrum disorders: a review and results from the CHARGE study. Int J Environ Res Public Health. 2013;10(8):3715-34.

  13. Mayer EA, Tillisch K, Gupta A. Gut/brain axis and the microbiota. J Clin Invest. 2015;125(3):926-38.

  14. Beard CM, Panser LA, Katusic SK. Is excess folic acid supplementation a risk factor for autism? Med Hypotheses. 2011;77(1):15-7.

  15. Office of the Commissioner. U.S. Food and Drug Administration [Internet]. Fda.gov. 2021 [citado: 4 de abril de 2009]. Disponible en: https://www.fda.gov/ Folic Acid Fortification: Fact and Folly.

  16. Home [Internet]. Who.int. [citado: 25 de enero de 2001]. Disponible en: https://www.who.int/ World Health Organization. Recent concerns regarding MMR vaccine.

  17. Taylor LE, Swerdfeger AL, Eslick GD. Vaccines are not associated with autism: An evidence-based meta-analysis of casecontrol and cohort studies. Vaccine. 2014;32(29):3623-9.

  18. Amaral DG, Schumann CM, Nordahl CW. Neuroanatomy of autism. Trends Neurosci. 2008;31(3):137-45.

  19. Hutsler JJ, Love T, Zhang H. Histological and magnetic resonance imaging assessment of cortical layering and thickness in autism spectrum disorders. Biol Psychiatry. 2007;61(4):449-57.

  20. Buxhoeveden DP, Semendeferi K, Buckwalter J, Schenker N, Switzer R, Courchesne E. Reduced minicolumns in the frontal cortex of patients with autism. Neuropathol Appl Neurobiol. 2006;32(5):483-91.

  21. Schumann CM, Amaral DG. Stereological analysis of amygdala neuron number in autism. J Neurosci. 2006; 26(29):7674-9.

  22. Geschwind DH. Autism: many genes, common pathways? Cell. 2008;135(3):391-5.

  23. Knudsen EI. Sensitive periods in the development of the brain and behavior. J Cogn Neurosci. 2004;16(8):1412-25.

  24. Levitt P. Structural and functional maturation of the developing primate brain. J Pediatr. 2003;143(4):35-45.

  25. Just MA, Cherkassky VL, Keller TA, Kana RK, Minshew NJ. Functional and anatomical cortical underconnectivity in autism: evidence from an FMRI study of an executive function task and corpus callosum morphometry. Cereb Cortex. 2007;17(4):951-61.

  26. Moreno-De-Luca A, Evans DW, Boomer KB, Hanson E, Bernier R, Goin-Kochel RP, et al. The role of parental cognitive, behavioral, and motor profiles in clinical variability in individuals with chromosome 16p11.2 deletions. JAMA Psychiatry. 2015;72(2):119-26.

  27. Shao Y, Cuccaro ML, Hauser ER, Raiford KL, Menold MM, Wolpert CM, et al. Fine mapping of autistic disorder to chromosome 15q11-q13 by use of phenotypic subtypes. Am J Hum Genet. 2003;72(3):539-48.

  28. Kullmann DM. Neurological channelopathies. Annu Rev Neurosci. 2010;33(1):151-72.

  29. Robinson EB, Koenen KC, McCormick MC, Munir K, Hallett V, Happé F, et al. A multivariate twin study of autistic traits in 12-year-olds: testing the fractionable autism triad hypothesis. Behav Genet. 2012;42(2):245-55.

  30. R. T, I R.: Epilepsy in autism. Lancet Neurol. 2002;1:352-358.

  31. Lecavalier L. Behavioral and emotional problems in young people with pervasive developmental disorders: relative prevalence, effects of subject characteristics, and empirical classification. J Autism Dev Disord. 2006;36(8):1101-14.

  32. First MB, Reed GM, Hyman SE, Saxena S. The development of the ICD-11 clinical descriptions and diagnostic guidelines for mental and behavioural disorders. World Psychiatry. 2015;14(1):82-90.

  33. Werner E, Dawson G. Validation of the phenomenon of autistic regression using home videotapes. Arch Gen Psychiatry. 2005;62(8):889-95.

  34. Tebartz van Elst L, Pick M, Biscaldi M, Fangmeier T, Riedel A. High-functioning autism spectrum disorder as a basic disorder in adult psychiatry and psychotherapy: psychopathological presentation, clinical relevance, and therapeutic concepts. Eur Arch Psychiatry Clin Neurosci. 2013;263 Suppl 2(S2): S189-96.

  35. Factor RS, Ryan SM, Farley JP, Ollendick TH, Scarpa A. Does the presence of anxiety and ADHD symptoms add to social impairment in children with autism spectrum disorder? J Autism Dev Disord. 2017;47(4):1122-34.

  36. Lovaas OI. Behavioral treatment and normal educational and intellectual functioning in young autistic children. J Consult Clin Psychol. 1987;55(1):3-9.

  37. Reichow B, Barton EE, Boyd BA, Hume K. Early intensive behavioral intervention (EIBI) for young children with autism spectrum disorders (ASD). Cochrane Database Syst Rev. 2012;10:CD009260.

  38. Hardan AY, Gengoux GW, Berquist KL, Libove RA, Ardel CM, Phillips J, et al. A randomized controlled trial of Pivotal Response Treatment Group for parents of children with autism. J Child Psychol Psychiatry. 2015;56(8):884-92.

  39. Virues-Ortega J, Julio FM, Pastor-Barriuso R. The TEACCH program for children and adults with autism: a meta-analysis of intervention studies. Clin Psychol Rev. 2013;33(8):940-53.

  40. Kirino E. Efficacy and tolerability of pharmacotherapy options for the treatment of irritability in autistic children. Clin Med Insights Pediatr. 2014;8:17-30.

  41. Wink LK, Early M, Schaefer T, Pottenger A, Horn P, McDougle CJ, et al. Body mass index change in autism spectrum disorders: comparison of treatment with risperidone and aripiprazole. J Child Adolesc Psychopharmacol. 2014;24(2):78-82.

  42. Kimura G, Kadoyama K, Brown JB, Nakamura T, Miki I, Nisiguchi K, et al. Antipsychotics-associated serious adverse events in children: an analysis of the FAERS database. Int J Med Sci. 2015;12(2):135-40.

  43. Lai M-C, Lombardo MV, Baron-Cohen S. Autism. Lancet. 2014;383(9920):896-910.

  44. McPheeters ML, Warren Z, Sathe N, Bruzek JL, Krishnaswami S, Jerome RN, et al. A systematic review of medical treatments for children with autism spectrum disorders. Pediatrics. 2011;127(5):e1312-21.

  45. Fiks AG, Mayne SL, Song L, Steffes J, Liu W, McCarn B, et al. Changing patterns of alpha agonist medication use in children and adolescents 2009-2011. J Child Adolesc Psychopharmacol. 2015;25(4):362-7.

  46. Williams K, Brignell A, Randall M, Silove N, Hazell P. Selective serotonin reuptake inhibitors (SSRIs) for autism spectrum disorders (ASD). Cochrane Database Syst Rev. 2013;(8):CD004677.

  47. Mouti A, Reddihough D, Marraffa C, Hazell P, Wray J, Lee K, et al. Fluoxetine for Autistic Behaviors (FAB trial): study protocol for a randomized controlled trial in children and adolescents with autism. Trials. 2014;15(1):230.

  48. Hardan AY, Fung LK, Libove RA, Obukhanych TV, Nair S, Herzenberg LA, et al. A randomized controlled pilot trial of oral N-acetylcysteine in children with autism. Biol Psychiatry. 2012;71(11):956-61.

  49. Nikoo M, Radnia H, Farokhnia M, Mohammadi M-R, Akhondzadeh S. N-acetylcysteine as an adjunctive therapy to risperidone for treatment of irritability in autism: a randomized, double-blind, placebo-controlled clinical trial of efficacy and safety. Clin Neuropharmacol. 2015;38(1):11-7.

  50. Rossignol DA, Frye RE. The use of medications approved for Alzheimer’s disease in autism spectrum disorder: A systematic review. Front Pediatr. 2014:87.

  51. Posey DJ, Kem DL, Swiezy NB, Sweeten TL, Wiegand RE, McDougle CJ. A pilot study of D-cycloserine in subjects with autistic disorder. Am J Psychiatry. 2004;161(11):2115-7.

  52. Urbano M, Okwara L, Manser P, Hartmann K, Herndon A, Deutsch SI. A trial of D-cycloserine to treat stereotypies in older adolescents and young adults with autism spectrum disorder. Clin Neuropharmacol. 2014;37(3):69-72.

  53. Urbano M, Okwara L, Manser P, Hartmann K, Deutsch SI. A trial of d-cycloserine to treat the social deficit in older adolescents and young adults with autism spectrum disorders. J Neuropsychiatry Clin Neurosci. 2015;27(2):133-8.

  54. Roy A, Roy M, Deb S, Unwin G, Roy A. Are opioid antagonists effective in attenuating the core symptoms of autism spectrum conditions in children: a systematic review: Opioid antagonists, autism, intellectual disability, children. J Intellect Disabil Res. 2015;59(4):293-306.

  55. Young LJ, Barrett CE. Neuroscience. Can oxytocin treat autism? Science. 2015;347(6224):825-6.

  56. Anagnostou E, Soorya L, Brian J, Dupuis A, Mankad D, Smile S, et al. Intranasal oxytocin in the treatment of autism spectrum disorders: a review of literature and early safety and efficacy data in youth. Brain Res. 2014;1580: 188-98.




2020     |     www.medigraphic.com